Quantum BioPharma Taps Anti Naked Short Selling Advocate, Scores Nationwide Distribution Deal for Alcohol Detox Brand unbuzzd
Kevin Malone joins the fight against naked short selling and market manipulation as Quantum’s unbuzzd™ heads for convenience store shelves across America.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) is doubling down on two fronts—market advocacy and product expansion. This week, the innovative biopharma firm announced a high-profile board advisor appointment while its licensee, Celly Nutrition Corp., recently landed a retail distribution deal with one of the most influential trade groups in the U.S. convenience store sector.
The moves come as Quantum continues to build momentum behind its two-pronged mission: develop groundbreaking treatments for neurodegenerative diseases and defend shareholder value against what it calls systemic market manipulation.
Kevin Malone Joins Quantum to Combat Naked Short Selling and Market Manipulation
On Tuesday, Quantum named Kevin Malone a strategic advisor to its board. Malone, a veteran financial advisor and founder of Malone Wealth, has made a name for himself as a fierce critic of naked short selling—an illegal trading practice in which shares are sold short without first being borrowed.
Malone, who witnessed firsthand during the 2021 GameStop (NYSE: GME) short squeeze, the financial damages suffered by retail investors after brokerages such as Robinhood (NASDAQ: HOOD) halted purchases of GME in an attempt to shield market makers and hedge funds from further losses, had this to say about joining Quantum’s board:
I’ve seen firsthand how naked short selling and the unlimited liquidity privileges granted to market makers can devastate my clients’ investments. In 2021, when multiple brokerages removed the buy button on GameStop, I witnessed millions of dollars in client nest eggs and retirements vanish—simply because Wall Street got caught cheating. That moment changed everything for me. I committed to becoming a fiduciary who actively fights against market corruption.
Malone brings decades of financial experience and grassroots credibility to Quantum’s fight. CEO Zeeshan Saeed welcomed the addition, noting the alignment between Malone’s advocacy and Quantum’s vision.
“We are thrilled and honored to welcome Kevin Malone as an advisor,” Saeed said. “His wealth of experience, especially in naked short squeeze strategies, will be an incredible addition to our team of experts fighting the banks and investors engaged in this type of stock trading activity and manipulation.”
Malone also pointed to Quantum’s clinical pipeline—particularly its efforts to cure multiple sclerosis—as a major draw.
“When I learned about Quantum’s mission and their work to cure MS, I immediately knew I wanted to be part of their fight,” he said. “This is the kind of battle worth joining.”
Also Read: Quantum BioPharma Reports Completion of Phase 1 Clinical Trial for MS Drug Lucid-21-302
unbuzzd™ Scores Landmark Retail Deal via AATAC
Just days earlier, Quantum’s licensee Celly Nutrition announced a breakthrough retail deal that could dramatically expand the availability of its flagship alcohol detox product, unbuzzd™.
Celly Nutrition secured a national distribution partnership with the Asian American Trade Associations Council (AATAC), a coalition that represents more than 80,000 retail locations—including brands like 7-Eleven (OTC: SVNDY), Circle K, Shell (NYSE: SHEL), and Chevron (NYSE: CVX).
“We are excited to partner with AATAC to further expand unbuzzd™’s retail presence,” said John Duffy, CEO of Celly Nutrition. “This collaboration provides access to top retail operators across the United States, helping to grow sales and making unbuzzd™ available to even more consumers.”
The partnership centers on unbuzzd™’s “On-the-Go Powder Stick Packs,” which contain a clinically validated formula that accelerates alcohol metabolism, restores mental clarity, and reduces symptoms of intoxication. A recent double-blind, placebo-controlled trial demonstrated the formula’s effectiveness in lowering blood alcohol concentration and supporting mental alertness.
Also Read: Quantum BioPharma Expands Reach With New unbuzzd Launch and Cutting-Edge MS Clinical Study
Wellness Recovery Takes the Spotlight
AATAC’s leadership expressed enthusiasm about unbuzzd™’s potential, especially as consumer demand for functional wellness products surges.
Sunil Capita, AATAC’s National Programs Director, stated:
The health and wellness category has grown significantly over recent years in our industry, and recovery products have become a leader within that category. Understandably, our Association wants to be at the forefront of this evolving trend, so we are very excited to see how well unbuzzd™ will perform in our retail sites. We would eventually like to see recovery products offered to U.S. consumers by thousands of our network retailers across the country.
If successful, the partnership could bring unbuzzd™ to thousands of convenience stores across the U.S., dramatically increasing the brand’s reach and potentially positioning it as a category leader.
From Advocacy to Innovation, Quantum Pushes Ahead
Quantum BioPharma continues to develop its lead drug candidate, Lucid-MS, a patented compound that has shown the ability to prevent and reverse myelin degradation—the core pathology of multiple sclerosis—in preclinical models. Through its strategic investment arm and stake in Celly Nutrition, the company is also generating revenue and exposure in consumer wellness.
Meanwhile, with Kevin Malone now on board, Quantum signals a growing commitment not just to science but also to stock market fairness.
The twin announcements—Malone’s appointment and the AATAC partnership—showcase Quantum’s evolving strategy: protect investor value while scaling health-focused innovation.
For shareholders and advocates alike, the message is clear. Quantum BioPharma doesn’t just want to change medicine. It wants to change the game.
Read Next: How This $4 Stock is Taking on Wall Street’s Big Banks with a $700 Million Lawsuit
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $20,000 for social media marketing and USD $7,500 per month for 3 months for investor relations by Quantum BioPharma Ltd.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
